Atezolizumab and bevacizumab with anticoagulant or antiplatelet therapy in hepatocellular carcinoma patients: Real‐world data for informed clinical decision‐making-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Atezolizumab and bevacizumab with anticoagulant or antiplatelet therapy in hepatocellular carcinoma patients: Real‐world data for informed clinical decision‐making

Published:2024-07-16 Issue:8 Volume:44 Page:1749-1750
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver International

Author:

Villeret François¹²^ORCID,Nahon Pierre³⁴⁵^ORCID

Affiliation:

1. Service d'Hépatologie, Institut d'Hépatologie de Lyon Hôpital de la Croix Rousse, Hospices Civils de Lyon Lyon France

2. INSERM U1052, CNRS UMR 5286 Université de Lyon 1 Lyon France

3. AP‐HP, Liver Unit Hôpitaux Universitaires Paris Seine Saint‐Denis Bobigny France

4. Université Sorbonne Paris Nord Bobigny France

5. Inserm, UMR‐1138 “Functional Genomics of Solid Tumors”, Centre de recherche des Cordeliers Université de Paris Paris France

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.15954

Reference12 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Global Epidemiology and Genetics of Hepatocellular Carcinoma

3. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications

4. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009

5. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP